Celmatix
23andMe Q1 Revenues Rise 23 Percent
The company said its revenue growth was primarily due to higher sales of its Personal Genome Service kit.
Celmatix Sues 23andMe for $100M Alleging Breach of Contract
The genomics-focused fertility management company claims that 23andMe failed to meet its contractual obligations within a research collaboration.
Evotec, Celmatix Partner on Women's Reproductive Health Drug Discovery
About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders.
Celmatix Forms Therapeutics Discovery Division
The new division — called Celmatix Biosciences — will focus on women's health indications with high unmet need including reproductive disorders and menopause.
Celmatix Partners With Onctotest-Teva to Offer Reproductive Health Genetic Test in Israel
The Fertilome test, a multigene sequencing panel, assesses a number of markers that have been associated with conditions that affect fertility.